OncoTargets and Therapy (Feb 2020)

The Ectopic Expression of SurvivinT34A and FilC Can Enhance the Oncolytic Effects of Vaccinia Virus in Murine Gastric Cancer

  • Wang M,
  • Luo Y,
  • Sun T,
  • Mao C,
  • Jiang Y,
  • Yu X,
  • Li Z,
  • Xie T,
  • Wu F,
  • Yan H,
  • Teng L

Journal volume & issue
Vol. Volume 13
pp. 1011 – 1025

Abstract

Read online

Minglong Wang,1,* Yanxi Luo,2,* Ting Sun,2 Chenyu Mao,1 Yili Jiang,2 Xiongfei Yu,1 Zhongqi Li,1 Tian Xie,3 Fusheng Wu,1 Hui Yan,2,3 Lisong Teng1 1Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou, People’s Republic of China; 3Holistic Integrative Pharmacy Institutes, Hangzhou Normal University, Hangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lisong TengDepartment of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, People’s Republic of ChinaEmail [email protected] YanInstitute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou 310013, People’s Republic of ChinaEmail [email protected]/Aims: Anti-tumor vaccines have been shown to be effective in cancer therapeutics ever since the anti-HPV vaccine was developed. Compared to conventional chemotherapy, anti-tumor vaccines can specifically target cancer cells and they have lower side effects. We developed a recombinant vaccinia virus (VACV) (Western Reserve) WR strain, and we tested its anti-tumor effects in an animal model.Methods: A recombinant VACV WR strain expressing mutant survivin T34A (SurT34A) and FilC was constructed and validated. Its oncolytic effect was tested in vitro using a CCK-8 assay, and its tolerance and anti-tumor effects were tested in a murine gastric cancer model. The proportion of lymphocytes in the spleen and tumor was determined after antibody-mediated immuno-depletion.Results: The recombinant VACV showed a stronger replication ability in tumor cells, and it was safe in vivo, even at high doses. The combination of vv-SurT34A and vv-FilC resulted in a stronger anti-tumor effect compared to either construct alone. However, the inhibitory effect of vv-SurT34A was stronger than the combination. The recombinant VACV activated the host immune response, as indicated by lymphocyte infiltration in the spleen and tumor tissues.Conclusion: The recombinant VACV WR strain expressing SurT34A and FilC is a safe and effective anti-tumor vaccine.Keywords: vaccinia virus WR strain, survivin T34A, FilC, anti-tumor effect

Keywords